A Study of Molecular Mimicry and Immunological Cross‐reactivity between Hepatitis B Surface Antigen and Myelin Mimics

Author:

Bogdanos Dimitrios-Petrou,Smith Heather,Ma Yun,Baum Harold,Mieli-Vergani Giorgina,Vergani Diego

Abstract

On the basis of the reported association between hepatitis B vaccination (HBvacc) and autoimmune demyelinating complications such as multiple sclerosis (MS), we have looked for aminoacid similarities between the small hepatitis B virus surface antigen (SHBsAg), and the MS‐autoantigens myelin basic protein (MBP) and myelin oligodendrocyte glycoprotein (MOG) that could serve as targets of immunological cross‐reactivity. Twenty‐mer peptides spanning 4 SHBsAg/MOG and 1 SHBsAg/MBP mimicking pairs, were constructed and tested by ELISA as targets of cross‐reactive responses. A total of 147 samples from 58 adults were collected before HBvacc (58/58), and post‐HBvacc (48/58 before the second and 41/58 before the third boost). Eighty‐seven sera from anti‐SHBsAg antibody negative patients with various diseases were tested as pathological controls. Reactivity to at least one of the SHBsAg peptides was found in 8 (14%) pre‐HBvacc subjects; amongst the remaining 50, reactivity to at least one of the SHBsAg peptides appeared in 47 (94%) post‐HBvacc. Reactivity to at least one of the MOG mimics was present in 4 (8%) pre‐HBvacc and in 30 (60%) post‐HBvacc (p < 0.001). Overall 30/50 (60%) vaccinees had SHBsAg/MOG double reactivity on at least one occasion compared to none before‐vaccination and in 2 (2%) of the pathological controls (p < 0.001 for both). SHBsAg/MOG double reactivity was cross‐reactive as confirmed by inhibition studies. At 6 months post‐vaccination, 3 of the 4 anti‐MOG reactive cases before vaccination and 7 of the 24 (29%) of the anti‐MOG reactive cases at 3 months post‐vaccination had lost their reactivity to MOG5-24. There was no reactivity to the SHBsAg/MBP mimics. None of the vaccinees reported symptoms of demyelinating disorders. In view of the observed SHBsAg/MOG cross‐reactivity, the vaccine′s possible role as an immunomodulator of viral/self cross‐reactivity must be further investigated.

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.7亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2025 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3